Healthcare provider profile · identity verified

Phyllidia M. Ku-Ruth, MD

Internal Medicine · PORTLAND, ME · NPI 1497724108

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	640	187
Levothyroxine Sodium	Levothyroxine Sodium	410	107
Rosuvastatin Calcium	Rosuvastatin Calcium	320	98
Lisinopril	Lisinopril	306	85
Metoprolol Succinate	Metoprolol Succinate	240	71
Omeprazole	Omeprazole	198	65
Amlodipine Besylate	Amlodipine Besylate	189	52
Losartan Potassium	Losartan Potassium	182	55
Bupropion Xl	Bupropion Hcl	154	41
Escitalopram Oxalate	Escitalopram Oxalate	136	40
Trazodone Hcl	Trazodone Hcl	134	44
Hydrochlorothiazide	Hydrochlorothiazide	130	41
Sertraline Hcl	Sertraline Hcl	128	36
Alendronate Sodium	Alendronate Sodium	124	44
Eliquis	Apixaban	122	31
Raloxifene Hcl	Raloxifene Hcl	112	28
Metformin Hcl Er	Metformin Hcl	96	30
Lorazepam	Lorazepam	93	42
Gabapentin	Gabapentin	87	28
Fluoxetine Hcl	Fluoxetine Hcl	86	22
Buspirone Hcl	Buspirone Hcl	78	25
Montelukast Sodium	Montelukast Sodium	74	24
Synthroid	Levothyroxine Sodium	73	20
Tramadol Hcl	Tramadol Hcl	73	22
Mirtazapine	Mirtazapine	71	23
Valacyclovir	Valacyclovir Hcl	69	29
Carvedilol	Carvedilol	68	21
Duloxetine Hcl	Duloxetine Hcl	67	24
Spironolactone	Spironolactone	64	22
Atenolol	Atenolol	60	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	60	16
Albuterol Sulfate Hfa	Albuterol Sulfate	53	37
Furosemide	Furosemide	53	19
Mounjaro	Tirzepatide	53	suppressed
Simvastatin	Simvastatin	52	18
Allopurinol	Allopurinol	51	14
Clonazepam	Clonazepam	51	18
Ezetimibe	Ezetimibe	49	20
Irbesartan	Irbesartan	48	19
Paxlovid	Nirmatrelvir/Ritonavir	48	47
Venlafaxine Hcl Er	Venlafaxine Hcl	46	suppressed
Citalopram Hbr	Citalopram Hydrobromide	44	12
Famotidine	Famotidine	44	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	43	13
Prednisone	Prednisone	40	31
Zolpidem Tartrate	Zolpidem Tartrate	39	20
Pantoprazole Sodium	Pantoprazole Sodium	37	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	18
Estradiol	Estradiol	35	20
Potassium Chloride	Potassium Chloride	35	13
Metformin Hcl	Metformin Hcl	33	suppressed
Valsartan	Valsartan	33	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Pregabalin	Pregabalin	31	suppressed
Topiramate	Topiramate	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Ozempic	Semaglutide	30	suppressed
Rybelsus	Semaglutide	30	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Jardiance	Empagliflozin	28	11
Wixela Inhub	Fluticasone Propion/Salmeterol	28	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	11
Ipratropium Bromide	Ipratropium Bromide	27	17
Doxycycline Hyclate	Doxycycline Hyclate	26	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	23
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	25	25
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Trulicity	Dulaglutide	25	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	21
Naltrexone Hcl	Naltrexone Hcl	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Linzess	Linaclotide	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	17
Terazosin Hcl	Terazosin Hcl	18	suppressed
Yuvafem	Estradiol	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Finasteride	Finasteride	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	16	suppressed
Nystatin	Nystatin	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	16	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Torsemide	Torsemide	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	suppressed
Diazepam	Diazepam	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Methylphenidate Er	Methylphenidate Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Glipizide	Glipizide	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error